Ultimately, Dr. Minn notes, success in immuno-oncology will be measured in multiple ways: Scientifically, by the depth of ...

Baseline stool metagenomic profiling in CheckMate 915 linked specific bacterial taxa with recurrence-free survival after ...

Fecal microbiota transplantation is an emerging strategy for modulating the gut microbiome to influence immunotherapy ...

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have identified a ...

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies. However, nearly half of patients show limited ...

Immune system activation and activity is regulated through stimulatory or inhibitory ligand-receptor interactions collectively termed immune checkpoints. 1 Stimulatory interactions give the immune ...

The timing of myocarditis onset during immunotherapy treatment for cancer may predict how likely a person is to die of the condition, according to retrospective study results.Patients who developed my ...

Immune checkpoint inhibitors (ICIs) have revolutionized the field of cancer immuno-oncology. ICIs act on cancer cells by blocking the interaction between immune checkpoint proteins on immune cells and ...

Metastatic colorectal cancer (mCRC) remains a leading cause of cancer-related mortality worldwide. While significant advances have been achieved with ...

The future of systemic therapy for cutaneous squamous cell carcinoma (CSCC) is rapidly evolving, with research focused on ...

LIfT BioSciences’ lead IMAN-based drug candidate is a groundbreaking next-generation immunotherapy designed to treat patients with treatment-resistant cancers London, – LIfT BioSciences (‘LIfT’ or ...